| abstract |
The present invention relates to a pharmaceutical composition for the treatment or control of medical disorders selected from neurological disorders and psychotic disorders, which is an inhibitor of phosphodiesterase type 10A, which alleviates the symptoms associated with said disorders, To the use of said compounds for the manufacture of medicaments. Formula I In the above formula (I), Q is O or S; X 1 is N or CH; X 2 is N or CR 7 ; X 3 is O, S, -X 4 = C (R 8 ) -, wherein C (R 8 ) is bonded to a carbon atom having R 2 or -X 5 = C (R 9 ) X 5 is bonded to a carbon atom having a R 2), and, X 4 is N or CR 9, and; X 5 is N; Het is selected from optionally substituted phenyl, monocyclic hetaryl and fused bicyclic hetaryl, and R 1 is especially hydrogen, halogen, OH, C 1 -C 4 -alkyl, trimethylsilyl, C 1 -C 4 -alkyl sulfanyl, C 1 -C 4 - alkoxy -C 1 -C 4 - alkyl, C 1 -C 4 - alkoxy, C 1 -C 4 - alkoxy -C 1 -C 4 - alkoxy and moiety Y 1 - Cyc < / RTI > 1 ; R 2 is especially hydrogen, halogen, OH, C 1 -C 4 - alkyl, trimethylsilyl, C 1 -C 4 - alkoxy -C 1 -C 4 - alkyl, C 1 -C 4 - alkoxy, C 1 -C 4 -Alkoxy-C 1 -C 4 -alkoxy, C 2 -C 4 -alkenyloxy and the like; A is one of the following groups A 1 , A 2 , A 3 , A 4 or A 5 : Wherein * represents the point of attachment to each of the Het and the nitrogen atom respectively; R 3 to R 9 , R 3e , R 3f , A ', Y 1 and Cyc 1 are as defined in the claims. |